
    
      An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy
      Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic
      Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease
    
  